Latest in Pharmacology and Impact to Cardiometabolic Disease | Guideline Directed Therapy for the Treatment of Obesity and the Reduction of Major Adverse Cardiovascular Events

Presented by Tracey H. Taveira, Pharm.D., CDOE, CVDOE

Description: This continuing education program focuses on advancing the understanding and management of obesity and associated cardiovascular risks. Participants will review the latest literature, emphasizing the role of GLP-1 receptor agonists in reducing major adverse cardiovascular events (MACE). The program will also explore the comparative effectiveness of novel obesity treatments, such as GLP-1 and GLP-1/GIP receptor agonists, against traditional weight loss medications. Additionally, attendees will gain practical insights into improving medication adherence by addressing common barriers, fostering effective patient provider communication, and implementing strategies to manage side effects and optimize medication tolerance. This overarching goal is to enhance clinical outcomes and support evidence-based practice in obesity care.

Learning Objectives: 

1. Review current guidelines and literature on the management of obesity and cardiovascular risk, with a focus on the use of GLP-1 receptor agonists to reduce major adverse cardiovascular events (MACE).
2. Compare outcomes of novel obesity treatments, including GLP-1 and GLP-1/GIP receptor agonists, against previously available medications for weight loss.
3. Develop strategies to improve medication adherence by understanding common barriers, promoting patient-provider communication, and implementing tips to manage side effects and optimize medication tolerance.

Recordings will be made available within 10 business days following each webinar. There is a 60-day viewing window for the recordings. This presentation series is sponsored by Novo Nordisk Inc. No credits (CEUs) are available for this free webinar series.